DongKook Life Science
Financials
Valuation Metrics
DongKook Life Science's Market Cap is ₩742B. At end of 2025 it was ₩1171B. Ranked #1490 of 2,421 in KR market (top 62%), #864 of 1,640 on KOSDAQ (top 53%), #160 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 69%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 74.20B KRW | KR#1,490/2,421 Sec#160/231 |
| Revenue | 117.75B KRW | KR#1,325/2,421 Sec#83/231 |
| Net Income | 4.97B KRW | KR#1,212/2,421 Sec#82/231 |
| Total Assets | 217.57B KRW | KR#1,251/2,421 Sec#92/231 |
| Net Assets | 132.70B KRW | KR#1,210/2,421 Sec#91/231 |
| Employees | 211 | KR#1,062/2,421 Sec#88/231 |
| Value | ||
| P/E | 14.92x | KR#1,041/2,421 Sec#61/231 |
| P/B | 0.56x | KR#902/2,421 Sec#46/231 |
| PEG | 0.05x | KR#321/2,421 Sec#17/231 |
| P/S | 0.63x | KR#1,075/2,421 Sec#50/231 |
| EV/EBITDA | 10.48x | KR#643/2,421 Sec#29/231 |
| FCF Yield | -7.08% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 3.75% | KR#1,257/2,421 Sec#86/231 |
| ROA | 2.29% | KR#1,166/2,421 Sec#86/231 |
| Op. Margin | 8.65% | KR#611/2,421 Sec#51/231 |
| Revenue Growth | -1.12% | KR#1,584/2,421 Sec#157/231 |
| Earnings Growth | 285.71% | KR#175/2,421 Sec#9/231 |
| Financial Health | ||
| Debt Ratio | 63.95% | KR#1,145/2,421 Sec#135/231 |
| Total Debt | 37.79B KRW | KR#1,123/2,421 Sec#79/231 |
| FCF | -5.26B KRW | KR#1,508/2,421 Sec#118/231 |
| Cash | 5.20B KRW | KR#1,986/2,421 Sec#183/231 |
| Current Ratio | 1.73x | KR#1,014/2,421 Sec#113/231 |
| Net Debt/EBITDA | 3.20x | KR#919/2,421 Sec#68/231 |
| Performance | ||
| 1Y Return | -46.73% | KR#1,984/2,421 Sec#176/231 |
| 1M Return | 4.98% | KR#756/2,421 Sec#55/231 |
| From 52W High | -47.21% | KR#1,260/2,421 Sec#95/231 |
| 1Y MDD | -49.48% | KR#962/2,421 Sec#77/231 |
| Trading | ||
| Volume | 14,992 shares | KR#1,732/2,421 Sec#169/231 |
| Trading Value | 34.7M KRW | KR#1,966/2,421 Sec#201/231 |
| Foreign Own. | 2.40% | KR#1,486/2,421 Sec#141/231 |
| Per Share | ||
| EPS | 156 KRW | KR#1,349/2,421 Sec#88/231 |
| BPS | 4,149 KRW | KR#1,633/2,421 Sec#119/231 |
Company Info
Dongguk Pharmaceutical Life Science, established in 2017 and listed on KOSDAQ in 2025, manufactures and sells contrast agents, and distributes medical devices and diagnostic equipment. As a specialized contrast agent company, it launched Korea's first First generic contrast agent, Pamiray, and has 17 partners in 25 countries. Leveraging its radiology expertise and sales network from its contrast agent business, the company is expanding its AI medical device business and providing Total Patient Care. It is headquartered in Gangnam-gu, Seoul.